Women at Higher Risk Post-Heart Attack

A shocking new study published in the *European Heart Journal* reveals that women prescribed beta-blockers following a heart attack without reduced left ventricular ejection fraction (LVEF) are at a staggering 45% greater risk of severe health issues—including death—compared to their male counterparts.

An Unequal Fight Against Cardiovascular Disease

With nearly 60 million women in the U.S. affected by cardiovascular disease (CVD), only 44% recognize it as a major health threat. Why the discrepancy? Predominantly male-centric clinical trials have overlooked vital differences in how treatments impact women, who often react poorly to these therapies.

The Alarming Findings of the REBOOT Trial

This landmark analysis assessed data from the REBOOT trial, involving over 8,400 patients. Among the female participants, those who took beta-blockers experienced a higher incidence of serious complications—approximately 30 cases of adverse events per 1,000 patients yearly, compared to 21 for those not on beta-blockers.

The Silent Killer: Lack of Gender-Specific Guidelines

Despite differences in how men and women respond to treatment, current medical guidelines treat beta-blocker use as gender-neutral. The study authors call for a pressing reevaluation of prescribing practices, particularly for women with normal heart function on higher doses of beta-blockers.

Urgent Call: More Inclusion Needed in Clinical Trials

The implications of these findings are profound: it's time to prioritize the inclusion of women in cardiovascular research and develop gender-specific treatment strategies. The health of millions of women depends on it.